

1 **Online Supplement** (Expanded Materials and Methods)

2

3

Part I: Methods

4

5 ***SA Node Cell Preparations and Electrophysiological Recordings***

6 Single, spindle-shaped, spontaneously beating SANs, isolated from the rabbit
7 hearts, using protocols approved by the Animal Care and Use Committee of our
8 institution, as previously described (11, 13), were studied in Tyrode's solution at
9 $35\pm 0.1^\circ\text{C}$ with a perfusion rate of 1-1.5 ml/min (chamber volume 300 μl). The perforated
10 patch-clamp technique with 50 $\mu\text{mol/L}$ β -escin4 (Sigma) added to the pipette solution
11 was used to record spontaneous APs with an Axopatch-1D patch-clamp amplifier (Axon
12 Instruments). The bath solution contained (in mmol/L): NaCl 140; KCl 5.4; MgCl_2 1;
13 HEPES 5; CaCl_2 1.8; and glucose 5.5; pH 7.4. The pipette solution contained (in
14 mmol/L) K-gluconate 120, NaCl 10, MgATP 5, HEPES 5, and KCl 20; pH 7.2. The AP
15 rate was measured prior to, and in response to specific CCh concentrations (10 to 1000
16 nmol/l), followed by the washout in the presence or absence of PTX in the absence or
17 presence of inhibition of I_f (CsCl) or $I_{K_{\text{ACH}}}$ inhibition (TQ) or during dual inhibition of
18 both $I_{K_{\text{ACH}}}$ and I_f .

19 ***Voltage clamp recordings of I_f , $I_{K_{\text{ACH}}}$ or $I_{Ca,L}$ currents***

20 The whole-cell I_f or CCh induced currents were detected with an Axopatch-100D
21 amplifier (Axon Instruments, Inc., Union City, CA) at 35°C , low pass-filtered at 1 kHz,
22 and sampled at 5 kHz with pCLAMP, version 6.0 software. Patch clamp pipette
23 resistance was 3–5 megohms. Pipette solution contained (in mmol/L): 120 K-gluconate, 5

24 NaCl, 5 MgATP; 5 HEPES; 20 KCl;. 5 phosphocreatine, 0.2 NaGTP, pH 7. The bath
25 solution contained (in mmol/L): NaCl 140; KCl 5.4; MgCl₂ 1; HEPES 5; CaCl₂ 1.8; and
26 glucose 5.5; pH 7.4. 1 μ M carbachol (CCh; Calbiochem) was added to the bath solution
27 to induce the CCh sensitive current. Bath solutions containing drugs were applied rapidly
28 via a 1.5 ml/min perfusion rate into an experimental chamber of 300 μ l total volume.
29 CCh-induced currents were measured in the voltage-clamp mode by applying voltage
30 pulses of 500 ms, within the voltage range of -110 mV to + 40 mV in 10 mV increments
31 starting from a holding potential -40 mV. To reduce interference between I_f and $I_{K_{ACh}}$
32 currents, CCh induced current was measured in the presence of 2 mM CsCl added to the
33 bath solution. To block CCh induced current we used an additional set of cells pretreated
34 for 3 hours in KB solution at +4 °C with 1 μ M tertiapin-Q, a specific $I_{K_{ACh}}$ inhibitor (TQ,
35 Sigma).

36 The ruptured patch-clamp technique was used to record L-type Ca²⁺ current, $I_{Ca,L}$,
37 using an Axopatch -200D patch-clamp amplifier (Axon Instruments, Foster City, CA).
38 Only spontaneous, regularly beating spindle-shaped SANC were chosen for $I_{Ca,L}$
39 recordings. The depolarizing voltage clamp pulses (300 ms) were applied from a holding
40 potential of -50 mV with increments of 10 mV in the range -40 to +40 mV. The bath
41 solution contained the following (in mmol/L): NaCl, 117; TEA-Cl, 20; CsCl, 5.4; MgCl₂,
42 1; HEPES, 5; CaCl₂, 1.8; 4-AP, 4; pH = 7.4; 10 μ mol/L tetrodotoxin and 4 mmol/L 4-
43 aminopyridine were added to block interfering currents. The pipette solution contained
44 the following (in mmol/L): NaCl, 10; TEA-Cl, 20; CsCl, 110; EGTA, 10; MgATP, 5;
45 HEPES, 10; pH, 7.2. To minimize the interference from rundown, $I_{Ca,L}$ was measured

46 every 11 seconds (step to 0 mV); the effect of CCh was measured after 2 min-CCh
47 superfusion and compared to the amplitude of $I_{Ca,L}$ immediately before CCh addition.

48 ***Confocal imaging of Ca releases***

49 SANC were placed on the stage of a Zeiss LSM-410 inverted confocal
50 microscope (Carl Zeiss, Inc., Germany) and loaded with fluo-3 AM (Molecular Probes,
51 Eugene, OR). All images were recorded in the linescan mode, with the scan line oriented
52 along the long axis of the cell, close to sarcolemmal membrane; images were processed
53 with IDL software (5.4, Research Systems, Boulder, CO) as described previously (2).

54 ***Western blot of phospholamban***

55 The detection of site-specific PLB phosphorylation was performed in SANC as
56 previously described (9). SANC suspensions were equally divided into 6-8 parts, and
57 each part was individually treated: with selected concentrations of CCh (1 nmol/l to 10
58 μ mol/l) or solvent as a control for 5 min at +35°C. After treatment, samples were
59 centrifuged; the pellet was fully solubilized in lysis buffer and then snap frozen in liquid
60 nitrogen and kept for further investigation. For detection of PLB, the pellet was boiled at
61 100°C to dissociate PLB into its monomeric form. Proteins were resolved by 7.5%
62 urea/SDS-PAGE gel and transferred (\sim 10 μ g protein/lane) to polyvinylidene difluoride
63 membranes (Amersham Pharmacia Biotech). To detect PLB phosphorylation, the
64 phosphorylation site-specific P-Ser-16 polyclonal antibody (1:10000, Badrilla) and HRP-
65 conjugated secondary anti-rabbit antibody (1:10000, Bio-Rad) were employed.
66 Membranes were exposed to the chemiluminescence reaction (ECL, Amersham
67 Pharmacia Biotech) and quantified with a video detection system (Bio-Rad). To detect
68 total PLB the same membranes were stripped with stripping buffer (Pierce), and

69 incubated with a total anti-PLB monoclonal (1:10,000) phospholamban antibody
70 (Badrilla).

71 *Adenylyl and Guanylyl cyclase activities*

72 SANC were exposed to CCh (100 to 1000 nmol/l) in the presence of non-specific
73 PDE inhibitor IBMX (100 μ mol/l); the reaction was stopped by adding 100 % cold
74 ethanol to the cell suspension according to the assay instruction. All groups, i.e. those
75 with or without IBMX were incubated for a total time of 25 min. In groups treated with
76 IBMX, drug was added immediately at the beginning of incubation. In groups that
77 received CCh, drug was introduced at the 20th min of total incubation time for the
78 remaining 5 min of incubation. At 25 min, cAMP/cGMP production was stopped by
79 adding 100% freezing cold ethanol. Cells were homogenized and then centrifuged at 14
80 g. The supernatant was used for cAMP or cGMP estimation using a cyclic AMP or cyclic
81 GMP (¹²⁵I) assay system (Amersham Bitotech, USA). Total protein concentration was
82 determined with a Bio-Rad system (Hercules, CA). The amount of the cAMP was
83 expressed as pmol/mg protein.

84 *Curve fitting procedure to determine the best fit value of IC₅₀ in normalized dose* 85 *response curves*

86 To determine the IC₅₀ CCh of a standard dose-response curve fitting model
87 (GraphPad Software, Inc. 2007) was applied to the average BRR dose response data for
88 CCh alone, for CCh plus the I_{KACH} inhibitor tertiapin-Q (TQ), and to the average dose
89 response curve for reduction of PLB phosphorylation by CCh. The standard dose-
90 response model uses four specific parameters: the minimum plateau, the maximum
91 plateau, the IC₅₀, and the slope factor (which is often constrained to a standard value) to

92 calculate the best fit normalized response curve. The "IC₅₀-(EC₅₀)-shift" model within the
93 Prism 5 software (GraphPad Software, Inc. 2007) was used to determine the IC₅₀ shift for
94 the CCh+TQ effect on BBR and PLB phosphorylation reduction, using the control CCh
95 effect on BRR served as the reference curve and a standart slope factor.

96

97

Part II: Numerical modeling

98

Rationale for the modeling

99 Previous numerical models of ChR stimulation effects on BRR (3, 14) have
100 formulated important CCh-induced changes of I_{K_{ACh}}, I_f, and I_{CaL}. The present study
101 explored the integration of CCh effects on these classical surface membrane mechanisms
102 and PKA-dependent effects of intracellular Ca²⁺ cycling via NCX current (I_{NCX}) in BRR
103 in response to CCh stimulation at the IC₅₀ CCh. We used the experimentally measured
104 changes of LCR characteristics (LCR period and LCR signal mass) to numerically predict
105 the respective I_{NCX} changes in response to CCh stimulation that cannot be measured
106 experimentally during spontaneous AP firing.

107

108

The numerical model

109 We used a modification of the numerical SANC model of primary rabbit SANC
110 (10) based on the Kurata et al. model (7) that we had previously developed. Our model
111 integrates an ensemble of individual multiple LCRs with other factors known to modulate
112 SANC automaticity, including the rate of acceleration via β-AR stimulation (10) and the
113 fine DD structure in rabbit SANC (1).

114

115 ***Model formulations to simulate BRR produced by CCh (100 nmol/l)***

116 Simulations of CCh-dependent ion currents.

117 We calculated changes in I_{CaL} , I_f , and I_{KACH} at 100 nM CCh using formulations
 118 suggested previously by Zhang et al. 2002 (14). In short, the fractional block b of I_{CaL} by
 119 CCh was calculated using the following Michaelis-Menton–type equation:

$$120 \quad b = b_{\max} [CCh] / (K_{0.5, Ca} + [CCh]),$$

121 where $b_{\max} = 0.56$ and $K_{0.5, Ca} = 90$ nmol/l.

122 The shift s (in mV) of the I_f activation curve by CCh was also described by a Michaelis-
 123 Menton–type equation:

$$124 \quad s = s_{\max} [CCh]^{n_f} / (K_{0.5, f}^{n_f} + [CCh]^{n_f}),$$

125 where $s_{\max} = -7.2$ mV, $n_f = 0.69$, and $K_{0.5, f} = 12.6$ nmol/l.

126 I_{KACH} was described as follows:

$$127 \quad I_{KACH} = g_{KACH} \{ [K]_e / (10 + [K]_e) \} \times \{ (V_m - E_K) / [1 + \exp((V_m - E_K - 140)F/2.5RT)] \},$$

128 where $[K]_e$ is the extracellular K^+ concentration, E_K is the K^+ equilibrium potential, and
 129 the conductance g_{KACH} is defined as follows:

$$130 \quad g_{KACH} = g_{KACH, \max} jk [CCh]^{n_{KACH}} / (K_{0.5, KACH}^{n_{KACH}} + [CCh]^{n_{KACH}}),$$

131 where $g_{KACH, \max} = 0.304615$ nS/pF (i.e. 0.0198 μ S per 65 pF cell in), $K_{0.5, KACH} = 280$
 132 nmol/l , $n_{KACH} = 1.5$. The I_{KACH} inactivation variables j and k are defined below:

$$133 \quad dj/dt = \alpha_j (1 - j) - \beta_j j$$

$$134 \quad dk/dt = \alpha_k (1 - k) - \beta_k k$$

135

136 where α_j , β_j , α_k , β_k are rate constants ($\alpha_j = 73.1$ s⁻¹, $\alpha_k = 3.7$ s⁻¹). β_k and β_j are voltage-
 137 dependent:

138
$$\beta_j = 120 / \{1 + \exp[-(V_m + 50)/15]\}$$

139
$$\beta_k = 5.82 / \{1 + \exp[-(V_m + 50)/15]\}$$

140

141 Simulation of the LCR changes.

142 Individual LCRs are generated in the model as originally described in Vinogradova et al.
 143 (10). In short, the entire sarcolemma with adjacent junctional SR is virtually divided into
 144 segments of an average LCR size as measured by confocal microscopy. Each segment is
 145 described by a separate set of variables approximating the “local” Ca^{2+} cycling, I_{CaL} and
 146 I_{NCX} . The model algorithm makes some local SR segments permeable to Ca^{2+} , with the
 147 release rate being described by a sinusoid function. The number of LCRs (N_{LCR}), which
 148 fire in the model during each cycle is 42, i.e. the average number of LCRs evaluated from
 149 LCR line scan confocal images in rabbit SANC (1). The moments of the LCR firing in
 150 the model reflect the LCR periods: they are normally distributed, with the distribution
 151 center and the spread being close to that observed experimentally. Although, this kind of
 152 modeling does not provide a mechanism for the LCR initiation, it has been successfully
 153 used to evaluate the impact of the LCRs on the I_{NCX} , the fine DD structure, and ultimately
 154 AP firing rate.

155 We changed the following model parameters of LCRs and Ca^{2+} SR pumping in
 156 accordance with the experimental results obtained at 100 nmol/l [CCh]:

157 1) N_{LCR} is decreased to $N_{\text{LCR,CCh}} = 42 \cdot 71.5/100 \sim 30$, respectively in line with the
 158 reduction of the LCR rate in our confocal measurements to 71.5% of control.

159 2) The effective LCR size (L_{LCR}) was directly estimated from our confocal measurements
 160 in this study, and for the basal conditions $L_{\text{LCR}} = 6.9 \mu\text{m}$. L_{LCR} at 100 nmol/l CCh was

161 estimated from the reduction of the LCR size to 72.6% of control: $L_{LCR,CCh} = 6.9 \mu\text{m} \cdot$
 162 $72.6/100 \sim 5 \mu\text{m}$.

163 3) The LCR period after 3 min of 100 nmol/l [CCh] increased on average to 158.8% of
 164 control. Therefore, we increased t_{phase} , the phase of the LCR occurrence in our model (i.e.
 165 the center of the Gaussian distribution of the LCR periods) from $t_{\text{phaseh}} = 260 \text{ ms}$ to
 166 $t_{\text{phase,CCh}} = 260 \text{ ms} \cdot 158.8/100 \sim 413 \text{ ms}$.

167 4) We decreased the SR pumping rate ($P_{\text{up}} = 0.012 \text{ M/s}$) by 40% to $P_{\text{up_CCh}} = 0.0072$
 168 M/s to match an experimental estimate for the decrease in the index of PKA-dependent
 169 phosphorylation signaling (also by $\sim 40\%$).

170

171 ***Model formulations to simulate BRR produced by CCh 100 nM and calyculin A***

172 Simulations of CCh-dependent ion currents.

173 We changed only phosphorylation-independent I_{KCh} and I_f changes induced by
 174 100 nM CCh as described above but I_{CaL} remained unchanged.

175 Simulation of the LCR changes.

176 We changed the following model parameters of LCRs and Ca^{2+} SR pumping in
 177 accordance with the experimental results obtained at 100 nmol/l [CCh] and ***calyculin A***:

178 1) N_{LCR} is decreased to $N_{LCR,CCh+CyA} = 42 \cdot 85.4/100 \sim 36$, respectively in line with the
 179 reduction of the LCR rate in our confocal measurements to 85.4% of control.

180 2) The effective LCR size (L_{LCR}) slightly increased to 107.7% of control: $L_{LCR,CCh+CyA} =$
 181 $6.9 \mu\text{m} \cdot 107.7/100 \sim 7.4 \mu\text{m}$.

182 3) The LCR period after 3 min of 100 nmol/l [CCh] increased on average to 110.8% of
 183 control. Therefore, we increased t_{phase} , the phase of the LCR occurrence in our model (i.e.

184 the center of the Gaussian distribution of the LCR periods) from $t_{\text{phaseh}} = 260$ ms to
 185 $t_{\text{phase,CCh+CyA}} = 260 \text{ ms} \cdot 110.8/100 \sim 288$ ms.

186 Other Ca^{2+} cycling parameters were identical in all simulations of basal and
 187 slowed AP firing (i.e. they remain the same as in our previous model (10)). Specifically,
 188 LCR period $\text{SD}=30$ ms, $t_{\text{width}}=60$ ms, $P_{\text{rel,inst}}=0.5 \text{ ms}^{-1}$, $P_{\text{rel,spont}}=4 \text{ ms}^{-1}$ $\tau_{\text{dif}}=0.07$ ms,
 189 $L_{\text{sub}}=0.04 \mu\text{m}$.

190 Other minor changes of the original model.

191 The model used in the present study, similar to the original Kurata et al. model (7)
 192 (version with $I_{\text{st}}=0$) but does not have background Ca^{2+} current and I_{st} . In fact, the non-
 193 selective steady current I_{st} has neither molecular identity, nor specific blockers.
 194 Furthermore, it exhibits many properties of I_{NCX} and I_{CaL} . Since Kurata et al. model (7)
 195 (“ $I_{\text{st}}=0$ ” version) has a longer than usual APD_{50} value of ~ 120 ms, we slightly accelerated
 196 I_{CaL} inactivation to get more realistic APD_{50} values from 90 to 100 ms (Table 1 in (7)):

$$197 \quad \tau_{\text{IL}} = 0.6 \cdot (257.1 \exp(-(V+32.5)/13.9)^2 + 44.3)$$

198 To avoid possible problems with “degeneracy” (i.e. the existence of a continuum of
 199 equilibrium points) and slow ion concentration drifts (4-6) (review (12)), we fixed
 200 intracellular $[\text{Na}^+]$ and $[\text{K}^+]$ to 8 mmol/l and 140 mmol/l, respectively, as suggested in the
 201 most recent 2003 Kurata et al. model version (8). Specific ion conductances in the model
 202 were as follows (in nS/pF): $g_{\text{CaL}}=0.29$; $g_{\text{bNa}}=0.003348$; $g_{\text{h}}=0.1125$; $g_{\text{CaT}}=0.2977$; g_{Kr}
 203 $=0.057474$; $g_{\text{Ks}}=0.0259$; $g_{\text{to}}=0.144$; $g_{\text{sus}}=0.016$; $g_{\text{KAch,max}}=0.304615$. $I_{\text{NaK,max}}=0.9$ pA/pF
 204 asnd $k_{\text{NaCa}}=125$ pA/pF.

205

206

207 **Online Supplement References**

208

- 209 1. **Bogdanov KY, Maltsev VA, Vinogradova TM, Lyashkov AE, Spurgeon HA,**
210 **Stern MD, and Lakatta EG.** Membrane potential fluctuations resulting from
211 submembrane Ca²⁺ releases in rabbit sinoatrial nodal cells impart an exponential phase
212 to the late diastolic depolarization that controls their chronotropic state. *Circ Res* 99: 979-
213 987, 2006.
- 214 2. **Bogdanov KY, Vinogradova TM, and Lakatta EG.** Sinoatrial nodal cell
215 ryanodine receptor and Na⁽⁺⁾-Ca⁽²⁺⁾ exchanger: molecular partners in pacemaker
216 regulation. *Circ Res* 88: 1254-1258, 2001.
- 217 3. **Demir SS, Clark JW, and Giles WR.** Parasympathetic modulation of sinoatrial
218 node pacemaker activity in rabbit heart: a unifying model. *Am J Physiol* 276: H2221-
219 2244, 1999.
- 220 4. **Hund TJ, Kucera JP, Otani NF, and Rudy Y.** Ionic charge conservation and
221 long-term steady state in the Luo-Rudy dynamic cell model. *Biophys J* 81: 3324-3331,
222 2001.
- 223 5. **Kneller J, Ramirez RJ, Chartier D, Courtemanche M, and Nattel S.** Time-
224 dependent transients in an ionically based mathematical model of the canine atrial action
225 potential. *Am J Physiol Heart Circ Physiol* 282: H1437-1451, 2002.
- 226 6. **Krogh-Madsen T, Schaffer P, Skriver AD, Taylor LK, Pelzmann B, Koidl B,**
227 **and Guevara MR.** An ionic model for rhythmic activity in small clusters of embryonic
228 chick ventricular cells. *Am J Physiol Heart Circ Physiol* 289: H398-413, 2005.

- 229 7. **Kurata Y, Hisatome I, Imanishi S, and Shibamoto T.** Dynamical description of
230 sinoatrial node pacemaking: improved mathematical model for primary pacemaker cell.
231 *Am J Physiol Heart Circ Physiol* 283: H2074-2101, 2002.
- 232 8. **Kurata Y, Hisatome I, Imanishi S, and Shibamoto T.** Roles of L-type Ca^{2+}
233 and delayed-rectifier K^{+} currents in sinoatrial node pacemaking: insights from stability
234 and bifurcation analyses of a mathematical model. *Am J Physiol Heart Circ Physiol* 285:
235 H2804-2819, 2003.
- 236 9. **Kuschel M, Zhou YY, Spurgeon HA, Bartel S, Karczewski P, Zhang SJ,**
237 **Krause EG, Lakatta EG, and Xiao RP.** beta2-adrenergic cAMP signaling is uncoupled
238 from phosphorylation of cytoplasmic proteins in canine heart. *Circulation* 99: 2458-2465,
239 1999.
- 240 10. **Vinogradova TM, Lyashkov AE, Zhu W, Ruknudin AM, Sirenko S, Yang D,**
241 **Deo S, Barlow M, Johnson S, Caffrey JL, Zhou YY, Xiao RP, Cheng H, Stern MD,**
242 **Maltsev VA, and Lakatta EG.** High basal protein kinase A-dependent phosphorylation
243 drives rhythmic internal Ca^{2+} store oscillations and spontaneous beating of cardiac
244 pacemaker cells. *Circ Res* 98: 505-514, 2006.
- 245 11. **Vinogradova TM, Zhou YY, Bogdanov KY, Yang D, Kuschel M, Cheng H,**
246 **and Xiao RP.** Sinoatrial node pacemaker activity requires Ca^{2+} /calmodulin-dependent
247 protein kinase II activation. *Circ Res* 87: 760-767, 2000.
- 248 12. **Wilders R.** Computer modelling of the sinoatrial node. *Med Biol Eng Comput* 45:
249 189-207, 2007.
- 250 13. **Younes A, Lyashkov A, Graham D, Sheydina A, Volkova M, Mitsak M,**
251 **Vinogradova T, Lukyanenko Y, Li Y, Ruknudin A, Boheler K, van Eyk J, and**

252 **Lakatta EG.** Ca²⁺-stimulated basal adenylyl cyclase activity localization in membrane
253 lipid microdomains of cardiac sinoatrial nodal pacemaker cells. *JBC* e-publication, 2008.

254 14. **Zhang H, Holden AV, Noble D, and Boyett MR.** Analysis of the chronotropic
255 effect of acetylcholine on sinoatrial node cells. *J Cardiovasc Electrophysiol* 13: 465-474,
256 2002.

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275 **Online supplement Figure Legends**

276 Fig.S-1. Representative examples of continuously recorded APs at varying
277 concentrations of CCh.

278 Fig. S-2 A. Representative control total current-voltage relationship, left traces;
279 total current-voltage relationship in the presence of CsCl, middle traces (same cell in left
280 traces after 2 min perfusion with CsCl); total CCh induced current-voltage relationship in
281 the presence of CsCl, right traces (same cell after 2 min perfusion with 1 μ M CCh with
282 solution containing 2 mM CsCl). B. Representative traces of total current-voltage
283 relationship in cell perfused with $I_{K_{ACh}}$ blocker TQ, left traces (a different cell pretreated
284 and superfused with 1 μ M tertapin-Q); total current-voltage relationship in a TQ treated
285 cell superfused with CsCl, middle traces; total current-voltage relationship in TQ treated
286 cell subsequently exposed to 1 μ M CCh in solution containing CsCl (right traces).

287 Fig. S-3. Representative continuous AP recordings from spontaneously beating
288 SANC exposed to various [CCh] in cells in which $I_{K_{ACh}}$ was disabled.

289 Fig. S-4. A. Suppression of L type Ca^{2+} current by 10 μ M CCh. A representative
290 example of L type Ca^{2+} current records in response to voltage clamp to 0 mV from
291 holding potential of -50 mV prior to and during CCh exposure. B. Average effects of
292 CCh to suppress L type Ca^{2+} current (n=4; * - p<0.05).

293 Fig. S-5. Schematic illustration of the interplay of Ca^{2+} , basal Ca^{2+} -activated AC, cAMP,
294 PDE activity and PKA activity, cast in the context of sarcoplasmic reticulum Ca^{2+} cycling, L type
295 Ca^{2+} channels and other ion channels. Ca^{2+} activation of basal AC activity results in a feed
296 forward “fail safe” system to generate cAMP and cAMP/PKA dependent phosphorylation. Ca^{2+}
297 cycling protein phosphorylation (PLB, Ryanodine Receptors, L type Ca^{2+} channels, and crosstalk
298 of these) generates local, spontaneous submembrane Ca^{2+} releases. Ca^{2+} activation of I_{NCX} during

299 DD initiates and initiates spontaneous SANC AP's, as reported previously (2-6, 7-10). Global
300 increases in cytoplasmic Ca^{2+} triggered by APs activate ACs. Ca^{2+} , cAMP or PKA-dependant
301 phosphorylation also modulates other ion channels. The dual basal Ca^{2+} /cAMP-PKA “feed-
302 forward” regulation is kept in check by a high basal PDE activity, which prevents cAMP/PKA
303 signaling to become excessive i.e., acts as negative feedback mechanism to prevent an excessive
304 basal beating rate, and to insure reserve cAMP/PKA modulation of spontaneous beating via
305 activation of β -ARs.